Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
4D Molecular Therapeutics, Inc.
| Metric | 4D Molecular Therapeutics, Inc. FDMTHealthcare |
|---|---|
| Quality Score | 60 / 100 |
| Revenue (latest) | $85M |
| Net income (latest) | −$140M |
| Operating margin | −187.2% |
| Net margin | −164.4% |
| Return on equity | −27.7% |
| Return on assets | −24.7% |
| Return on capital (ROCE) | −30.5% |
| Debt / equity | 0.12× |
| Revenue growth (YoY) | 230194.6% |
| Altman Z″ (distress) | 6.96 |
| Accruals / assets | −5.5% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.